TMPRSS2-ERG融合基因在淋巴结转移前列腺癌中的阳性率及与生存的关系

doi:10.3969/j.issn.1006-7795.2019.01.013

摘要/Abstract

摘要： 目的研究TMPRSS2-ERG融合基因在淋巴结阳性前列腺癌中的分布以及对其预后的意义。方法收集2008年1月至2012年12月前列腺癌根治术后，术后病理提示淋巴结转移的标本50例。所有患者术后均接受内分泌治疗。利用荧光原位杂交技术检测标本中TMPRSS2-ERG融合基因。收集患者各种肿瘤特征（Gleason评分、分期）、有无生化复发、疾病特异性和总体生存率。比较融合基因阳性和阴性患者的临床病理资料分布及预后差异。结果 19例（38%）原发性肿瘤中检测到TMPRSS2-ERG融合基因。转移淋巴结中有16例（32%）出现融合基因。原发肿瘤与转移灶TMPRSS2-ERG状态一致性较好（Kappa=0.73）。在COX分析中，原发肿瘤中TMPRSS2-ERG融合基因与Gleason评分是生化复发的预测因素。在生存分析中，原发肿瘤/淋巴结融合基因（+/+）组与原发肿瘤/淋巴结融合基因（+/-）组预后低于原发肿瘤/淋巴结融合基因（-/-）组，无生化复发率差异存在统计学意义（P=0.03）。结论 TMPRSS2-ERG融合基因在伴有淋巴结转移的原发性前列腺癌中阳性率38%。原发肿瘤与淋巴结转移灶中TMPRRS2-ERG融合基因具有较好的一致性。原发肿瘤TMPRSS2-ERG融合基因阳性的患者预后较差。

关键词: TMPRSS2-ERG融合基因, 前列腺癌, 转移, 生存期

Abstract: Objective To investigate the distribution and prognostic significance of TMPRSS2-ERG fusion gene in lymph node-positive prostate cancer. Methods Fifty cases of lymph node metastasis after radical prostatectomy from January 2008 to December 2012 were collected. All patients received endocrine therapy after operation. The TMPRRS2-ERG fusion gene was detected with fluorescence in situ hybridization. The data were correlated with various tumor features (Gleason score, stage) and biochemical recurrence-free, disease-specificity, and overall survival. The distribution of clinicopathological data and prognosis of patients were compared with each other for the patients with positive and negative fusion genes. Results The TMPRSS2-ERG fusion gene was detected in 19 cases (38%) of the primary tumors. Fusion genes were present in 16 cases (32%) of the metastatic lymph nodes. The primary tumor and metastatic lesion TMPRSS2-ERG status was in good agreement (Kappa=0.73). The TMPRSS2-ERG fusion gene and Gleason score in primary tumors in COX analysis were predictors of biochemical recurrence. In survival analysis, the prognosis of primary tumors/lymph node fusion gene (+/+) group and primary tumors/lymph node fusion gene (+/-) group was lower than that of primary tumors/lymph node fusion gene (-/-) group, with significant difference in the non-biochemical recurrence rate (P=0.03). Conclusion The positive rate of TMPRSS2-ERG fusion gene in primary prostate cancer with lymph node metastasis was 38%. The fusion gene of TMPRRS2-ERG in primary tumors and lymph node metastases had good consistency (Kappa=0.73). Patients with positive primary tumor TMPRSS2-ERG fusion gene have a poor prognosis.

Key words: TMPRSS2-ERG, prostate cancer, metastases, survival

中图分类号:

R737.25

谢英伟, 金世鹏, 闫伟, 王伟, 平浩, 刘跃新. TMPRSS2-ERG融合基因在淋巴结转移前列腺癌中的阳性率及与生存的关系[J]. 首都医科大学学报, 2019, 40(1): 72-77.

Xie Yingwei, Jin Shipeng, Yan Wei, Wang Wei, Ping Hao, Liu Yuexin. Prevalence and prognostic significance of TMPRSS2-ERG fusion gene in prostate cancer with lymph node metastasis[J]. Journal of Capital Medical University, 2019, 40(1): 72-77.

参考文献

[1] 韩苏军. 中国前列腺癌发病及死亡现状和流行趋势分析[D]. 北京:北京协和医学院, 2015.
[2] 赫捷, 陈万青. 2012中国肿瘤登记年报[M]. 北京:军事医学科学出版社, 2012.
[3] Kumar-Sinha C, Tomlins S A, Chinnaiyan A M. Recurrent gene fusions in prostate cancer[J]. Nat Rev Cancer, 2008, 8(7):497-511.
[4] Tomlins S A, Rhodes D R, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer[J]. Science, 2005, 310(5748):644-648.
[5] Minner S, Enodien M, Sirma H, et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy[J]. Clin Cancer Res, 2011, 17(18):5878-5888.
[6] Furusato B, van Leenders G J, Trapman J, et al. Immunohistochemical ETS-related gene detection in a Japanese prostate cancer cohort:diagnostic use in Japanese prostate cancer patients[J]. Pathol Int, 2011, 61(7):409-414.
[7] Suh J H, Park J W, Lee C, et al. ERG immunohistochemistry and clinicopathologic characteristics in Korean prostate adenocarcinoma patients[J]. Korean J Pathol, 2012, 46(5):423-428.
[8] 陶晶, 张豪杰, 肖立,等. TMPRSS2-ERG融合基因在国人前列腺癌组织中的表达及其临床意义[J]. 中国男科学杂志, 2016, 30(12):16-20.
[9] Qi M, Yang X, Zhang F, et al. ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients[J]. PLoS One, 2014, 9(2):e84959.
[10] Dong J, Xiao L, Sheng L, et al. TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China[J]. Asian Pac J Cancer Prev, 2014, 15(7):3099-3103.
[11] 陶晶. 前列腺癌TMPRSS2-ETS融合基因的研究进展[J]. 中国男科学杂志, 2015, 29(8):55-58.
[12] Burdova A, Bouchal J, Tavandzis S, et al. TMPRSS2-ERG gene fusion in prostate cancer[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2014, 158(4):502-510.
[13] Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer[J]. Oncogene, 2008, 27(3):253-263.
[14] Gopalan A, Leversha M A, Satagopan J M, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy[J]. Cancer Res, 2009, 69(4):1400-1406.
[15] Cheng L, Song S Y, Pretlow T G, et al. Evidence of independent origin of multiple tumors from patients with prostate cancer[J]. J Nat Cancer Inst, 1998, 90(3):233-237.
[16] Guo C C, Zuo G, Cao D, et al. Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion[J]. Mod Pathol, 2009, 22(7):866-871.
[17] Perner S, Svensson M A, Hossain R R, et al. ERG rearrangement metastasis patterns in locally advanced prostate cancer[J]. Urology, 2010, 75(4):762-767.
[18] 刘彼得, 顾晓, 周广臣,等. TMPRSS2-ERG及MMP-9基因对前列腺癌侵袭性的影响[J]. 基础医学与临床, 2016, 36(4):508-512.
[19] Mehra R, Tomlins S A, Yu J, et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer[J]. Cancer Res, 2008, 68(10):3584-3590.
[20] Saramäki O R, Harjula A E, Martikainen P M, et al. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis[J]. Clin Cancer Res, 2008, 14(11):3395-3400.
[21] Leinonen K A, Saramaki O R, Furusato B, et al. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer[J]. Cancer Epidemiol Biomarkers & Prev, 2013, 22(12):2333-2344.
[22] Kim S H, Kim S H, Young J J, et al. Overexpression of ERG and wild-type PTEN are associated with favorable clinical prognosis and low biochemical recurrence in prostate cancer[J]. PLoS One, 2015, 10(4):e0122498.
[23] Hagen R M, Adamo P, Karamat S, et al. Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples:association with seminal vesicle invasion and biochemical recurrence[J]. Am J Clin Pathol, 2014, 142(4):533-540.
[24] Font-Tello A, Juanpere N, de Muga S, et al. Association of ERG and TMPRSS2-ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels[J]. Prostate, 2015, 75(11):1216-1226.
[25] Taris M, Irani J, Blanchet P, et al. ERG expression in prostate cancer:the prognostic paradox[J]. Prostate, 2014, 74(15):1481-1487.
[26] Nishijima J, Hara T, Ikemoto K, et al. Clinical significance of ERG rearrangement subtype and its association with increased p53 expression in Japanese and German prostate cancer[J]. Neoplasma, 2015, 62(2):278-287.